Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
Neuroblastoma|Osteosarcoma|Other Solid Tumor Cancers
BIOLOGICAL: Humanized 3F8 Bispecific Antibody|OTHER: Blood draw
Dose Limiting Toxicities (DLTs) Phase I, Summary of DLTs in DLT evaluable subjects., Days 1 through 28 in cycle 1
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).